{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:13:15Z","timestamp":1771297995338,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,6,14]],"date-time":"2014-06-14T00:00:00Z","timestamp":1402704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data are limited on the efficacy and safety of bortezomib for the treatment of <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> following <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content> for pediatric acquired or <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>. Retrospective chart review identified patients who received bortezomib for acute (n\u00a0=\u00a03, within two wk of diagnosis) and chronic (n\u00a0=\u00a01, three months after diagnosis) <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> or as part of a desensitization regimen (n\u00a0=\u00a01). Bortezomib was associated with a 3\u201366% reduction in class I <jats:styled-content style=\"fixed-case\">DSA<\/jats:styled-content> and a 7\u201382% reduction in class <jats:styled-content style=\"fixed-case\">II DSA<\/jats:styled-content>. Two of the three acute <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> cases resolved by the first follow\u2010up biopsy. Two patients with <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> resolution are currently well. One patient developed a second episode of <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content>, which was unresponsive to bortezomib therapy and required retransplantation for progressive coronary allograft vasculopathy. One patient died shortly after the third cycle from multi\u2010organ failure. The desensitization patient showed transient <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content> reduction with two cycles, but died five months after transplant from sepsis. Complications included infection (3\/5), peripheral neuropathy (2\/5), <jats:styled-content style=\"fixed-case\">AKI<\/jats:styled-content> (2\/5), and thrombocytopenia (3\/5). Adverse events appear more common in critically ill patients. Bortezomib therapy resulted in variable <jats:styled-content style=\"fixed-case\">DSA<\/jats:styled-content> reduction and <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> resolution in <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content> secondary to pediatric acquired or <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/petr.12300","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T18:35:20Z","timestamp":1402943720000},"page":"469-476","source":"Crossref","is-referenced-by-count":14,"title":["Bortezomib use in a pediatric cardiac transplant center"],"prefix":"10.1111","volume":"18","author":[{"given":"Matthew D.","family":"Zinn","sequence":"first","affiliation":[{"name":"Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"L'Ecuyer","sequence":"additional","affiliation":[{"name":"University of Virginia Children's Hospital Charlottesville VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar R.","family":"Fagoaga","sequence":"additional","affiliation":[{"name":"Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.08.005"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.12.009"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.03.015"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.07.011"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)00472-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2009.07.001"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.07.042"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.09.005"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.03.031"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2007.05.095"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.11.011"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-011-9928-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.07.052"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.09.003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2012.01690.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq502"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02461.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318190af83"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181c6ff8d"},{"key":"e_1_2_8_21_1","first-page":"323","article-title":"A summary of bortezomib use in transplantation across 29 centers","author":"Everly MJ","year":"2009","journal-title":"Clin Transpl"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e328348c0e5"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN107156"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181fdd9b0"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181a4b91b"},{"key":"e_1_2_8_26_1","first-page":"343","article-title":"Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC","author":"Pavlakis M","year":"2009","journal-title":"Clin Transpl"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02968.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149385"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.03.019"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01543.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.5858\/2009-0581-OA.1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12199"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181856f98"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.08.011"},{"key":"e_1_2_8_36_1","first-page":"475","article-title":"Bortezomib for refractory antibody\u2010mediated cardiac allograft rejection","author":"Eckman PM","year":"2009","journal-title":"Clin Transpl"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31823f7eea"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.08.009"},{"key":"e_1_2_8_39_1","first-page":"347","article-title":"Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation\u2013a case report","author":"Patel JK","year":"2009","journal-title":"Clin Transpl"},{"key":"e_1_2_8_40_1","first-page":"393","article-title":"Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants","author":"Weston M","year":"2009","journal-title":"Clin Transpl"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpetr.12300","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.12300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:11:55Z","timestamp":1695510715000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.12300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,14]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/petr.12300"],"URL":"https:\/\/doi.org\/10.1111\/petr.12300","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,14]]}}}